SCHEMBL23724972

SCHEMBL23724972

O=C(O)c1ccc2c(=O)n(-c3cccc(Br)c3)cnc2c1

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
FGFR1 P11362 4/20 0.52
ESR1 P03372 2/20 0.47
ESR2 Q92731 2/20 0.47
THRB P10828 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
PDE4A P27815 1/20 0.40
CSNK2A1 P68400 1/20 0.40
ALKBH5 Q6P6C2 1/20 0.40
HPD P32754 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2335780 0.84 FGFR1 (0.75) MEN1KMT2AFGFR1THRBHPGD
SCHEMBL23725281 0.82 MEN1 (0.57) MEN1KMT2AFGFR1ESR1ESR2
SCHEMBL12821893 0.81 FGFR1 (0.75) MEN1KMT2AFGFR1THRBHPGD
Propane SCHEMBL2648345 0.80 FGFR1 (0.68) FGFR1THRBHPGDSMN1; SMN2ALDH1A1
SCHEMBL23725339 0.79 MEN1 (0.68) MEN1KMT2AFGFR1ESR1ESR2
SCHEMBL23726015 0.78 HPGD (0.46) MEN1KMT2AFGFR1ESR1ESR2
SCHEMBL29026031 0.78 HPGD (0.53) MEN1KMT2AFGFR1THRBHPGD
SCHEMBL31022762 0.78 HPGD (0.53) MEN1KMT2AFGFR1THRBHPGD
SCHEMBL28738321 0.73 ESR1 (0.63) MEN1KMT2AESR1ESR2GAA
SCHEMBL12617104 0.73 MRGPRX4 (0.56) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
EP-4100381-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-12-14 EP disclosed
CN-115413275-A Substituted 1,1 , -biphenyl compounds and methods of use thereof 爱彼特生物制药公司 2022-11-29 CN disclosed
WO-2021158481-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME HAVCR2, HMBS, VHL MEN1 896/4885KMT2A 346/4885FGFR1 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.